[ad_1]
AsianScientist (February 4, 2019) – Japan-based PHCD (PHCD) has announced the signing of a definitive agreement with Thermo Fisher Scientific (Thermo Fisher) for the acquisition of its anatomical pathology business for approximately US $ 1.14 billion. US dollars.
Thermo Fisher's anatomical pathology activities provide laboratories around the world with microscope slides, instruments and consumables to accelerate life science research, solve complex badytical problems, improve patient diagnoses, distribute drugs and to increase the productivity of the laboratories. Prior to the PHCHD acquisition, the department was part of Thermo Fisher's Specialty Diagnostics segment, which employed approximately 1,200 people in the United States, Europe and China.
PHCHD currently expects to close the transaction with Thermo Fisher in the second quarter of 2019, subject to customary closing conditions and the receipt of applicable regulatory approvals. Once finalized, the acquisition is expected to expand PHCHD's products and services in the areas of diabetes care, diagnostics, life sciences and health.
"We are pleased to have signed the agreement with Thermo Fisher Scientific. Their anatomical pathology business is growing steadily with a strong customer base in global hospital markets, particularly in the United States. It's a solid company with good growth potential and we believe it will create value for our stakeholders as part of our growing portfolio of diagnostics and healthcare, "said Dr. Hidehito Kotani, CEO of PHCHD.
—
Source: PHC Holdings Corporation; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
[ad_2]
Source link
